<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.1d3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">76272</article-id><article-id pub-id-type="doi">10.7554/eLife.76272</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Epidemiology and Global Health</subject></subj-group><subj-group subj-group-type="heading"><subject>Genetics and Genomics</subject></subj-group></article-categories><title-group><article-title>Integrated analyses of growth differentiation Factor-15 concentration and cardiometabolic diseases in humans</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="author-267730"><name><surname>Lemmelä</surname><given-names>Susanna</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-263656"><name><surname>Wigmore</surname><given-names>Eleanor May</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-0864-9990</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="corresp" rid="cor2">*</xref><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-267731"><name><surname>Benner</surname><given-names>Christian</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-117565"><name><surname>Havulinna</surname><given-names>Aki S</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-4787-8959</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-267732"><name><surname>Ong</surname><given-names>Rachel MY</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-267733"><name><surname>Kempf</surname><given-names>Tibor</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-267734"><name><surname>Wollert</surname><given-names>Kai C</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-267735"><name><surname>Blankenberg</surname><given-names>Stefan</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-267736"><name><surname>Zeller</surname><given-names>Tanja</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-214701"><name><surname>Peters</surname><given-names>James Edward</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-9415-3440</contrib-id><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-117568"><name><surname>Salomaa</surname><given-names>Veikko</given-names></name><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-267737"><name><surname>Fritsch</surname><given-names>Maria</given-names></name><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="fn" rid="conf4"/></contrib><contrib contrib-type="author" id="author-267738"><name><surname>March</surname><given-names>Ruth</given-names></name><xref ref-type="aff" rid="aff10">10</xref><xref ref-type="fn" rid="conf5"/></contrib><contrib contrib-type="author" id="author-267739"><name><surname>Palotie</surname><given-names>Aarno</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-267740"><name><surname>Daly</surname><given-names>Mark</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-126253"><name><surname>Butterworth</surname><given-names>Adam</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-267741"><name><surname>Kinnunen</surname><given-names>Mervi</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-267742"><name><surname>Paul</surname><given-names>Dirk S</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-8230-0116</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf6"/></contrib><contrib contrib-type="author" id="author-267743"><name><surname>Matakidou</surname><given-names>Athena</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf7"/></contrib><aff id="aff1"><institution content-type="dept">Institute for Molecular Medicine Finland</institution>, <institution>University of Helsinki</institution>, <addr-line><named-content content-type="city">Helsinki</named-content></addr-line>, <country>Finland</country></aff><aff id="aff2"><institution content-type="dept">Centre for Genomics Research</institution>, <institution>AstraZeneca</institution>, <addr-line><named-content content-type="city">Cambridge</named-content></addr-line>, <country>United Kingdom</country></aff><aff id="aff3"><institution content-type="dept">Institute of Molecular Medicine Finland</institution>, <institution>University of Helsinki</institution>, <addr-line><named-content content-type="city">Helsinki</named-content></addr-line>, <country>Finland</country></aff><aff id="aff4"><institution content-type="dept">British Heart Foundation Cardiovascular Epidemiology Unit</institution>, <institution>University of Cambridge</institution>, <addr-line><named-content content-type="city">Cambridge</named-content></addr-line>, <country>United Kingdom</country></aff><aff id="aff5"><institution content-type="dept">Department of Cardiology and Angiology</institution>, <institution>Hannover Medical School</institution>, <addr-line><named-content content-type="city">Hannover</named-content></addr-line>, <country>Germany</country></aff><aff id="aff6"><institution content-type="dept">Clinic for General and Interventional Cardiology</institution>, <institution>University Medical Center Hamburg-Eppendorf</institution>, <addr-line><named-content content-type="city">Hamburg</named-content></addr-line>, <country>Germany</country></aff><aff id="aff7"><institution content-type="dept">Department of Immunology and Inflammation</institution>, <institution>Imperial College London</institution>, <addr-line><named-content content-type="city">London</named-content></addr-line>, <country>United Kingdom</country></aff><aff id="aff8"><institution>National Institute of Health and Family Welfare</institution>, <addr-line><named-content content-type="city">Helsinki</named-content></addr-line>, <country>Finland</country></aff><aff id="aff9"><institution content-type="dept">esearch and Early Development Cardiovascular, Renal and Metabolism</institution>, <institution>AstraZeneca</institution>, <addr-line><named-content content-type="city">Gothenburg</named-content></addr-line>, <country>Sweden</country></aff><aff id="aff10"><institution content-type="dept">Precision Medicine</institution>, <institution>AstraZeneca</institution>, <addr-line><named-content content-type="city">Cambridge</named-content></addr-line>, <country>United Kingdom</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-136599"><name><surname>Janus</surname><given-names>Edward D</given-names></name><role>Reviewing editor</role><aff><institution>University of Melbourne</institution>, <country>Australia</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>susanna.lemmela@helsinki.fi</email> (SL);</corresp><corresp id="cor2"><label>*</label>For correspondence: <email>eleanor.wigmore@astrazeneca.com</email> (EW);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>02</day><month>08</month><year>2022</year></pub-date><volume>11</volume><elocation-id>e76272</elocation-id><history><date date-type="received"><day>10</day><month>12</month><year>2021</year></date><date date-type="accepted"><day>01</day><month>08</month><year>2022</year></date></history><permissions><copyright-statement>© 2022, Lemmelä et al</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Lemmelä et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-76272-v1.pdf"/><abstract><p>Growth differentiation factor 15 (GDF15) is a stress response cytokine that is elevated in several cardiometabolic diseases and has attracted interest as a potential therapeutic target. To further explore the association of GDF15 with human disease, we conducted a broad study into the phenotypic and genetic correlates of GDF15 concentration in up to 14,099 individuals. Assessment of 772 traits across 6,610 participants in FINRISK identified associations of GDF15 concentration with a range of phenotypes including all-cause mortality, cardiometabolic disease, respiratory diseases and psychiatric disorders as well as inflammatory markers. A meta-analysis of genome-wide association studies (GWAS) of GDF15 concentration across 3 different assay platforms (n=14,099) confirmed significant heterogeneity due to a common missense variant rs1058587 in <italic>GDF15</italic>, potentially due to epitope-binding artefacts. After conditioning on rs1058587, statistical fine-mapping identified 4 independent putative causal signals at the locus. Mendelian randomisation (MR) analysis found evidence of a causal relationship between GDF15 concentration and high-density lipoprotein (HDL) but not body mass index (BMI). Using reverse MR, we identified a potential causal association of BMI on GDF15 (IVW <italic>p</italic><sub>FDR</sub>=0.0040). Taken together, our data do not support a role for elevated GDF15 concentrations as a causal factor in human cardiometabolic disease but support its role as a biomarker of metabolic stress.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100018956</institution-id><institution>NIHR Cambridge Biomedical Research Centre</institution></institution-wrap></funding-source><award-id>BRC-1215-20014</award-id><principal-award-recipient><name><surname>Ong</surname><given-names>Rachel MY</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100005633</institution-id><institution>Sydäntutkimussäätiö</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Salomaa</surname><given-names>Veikko</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>Eleanor May Wigmore, is an employee of AstraZeneca.</p></fn><fn fn-type="conflict" id="conf3"><p>Rachel MY Ong, is currently an employee of GlaxoSmithKline (although was not when this work was carried out).</p></fn><fn fn-type="conflict" id="conf4"><p>Maria Fritsch, MF is an employee of AstraZeneca.</p></fn><fn fn-type="conflict" id="conf5"><p>Ruth March, RM is an employee of AstraZeneca.</p></fn><fn fn-type="conflict" id="conf6"><p>Dirk S Paul, is an employee of AstraZeneca.</p></fn><fn fn-type="conflict" id="conf7"><p>Athena Matakidou, is an employee of AstraZeneca.</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Human subjects: FINRISK study was approved by the Ethics Committee of Helsinki and Uusimaa Hospital District.Informed consent was obtained from all participants and the INTERVAL study was approved by the National Research Ethics Service (11/EE/0538).All study participants provided informed consent and the UK Biobank has approval from the North-West Multi-centre Research Ethics Committee (MREC; 11/NW/0382).</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>Participant-level genotype and phenotype data from UK Biobank are available by application: https://www.ukbiobank.ac.uk/enable-your-research/apply-for-access.Participant-level genotype and phenotype data (as part of the FinnGen consortium) are available by application: https://www.finngen.fi/en/access_results.INTERVAL-SomaScan participant-level genotype and protein data, and full summary association results from the genetic analysis are available through the European Genotype Archive (accession number EGA00001002555). Summary association results are also publically available at http://www.phpc.cam.ac.uk/ceu/proteins/, through PhenoScanner (http://www.phenoscanner.medschl.cam.ac.uk) and from the NHGRI-EBI GWAS Catalog (https://www.ebi.ac.uk/gwas/downloads/summary-statistics).INTERVAL-Olink summary association results are publically available at http://www.phpc.cam.ac.uk/ceu/proteins/.</p><p>The following previously published datasets were used:</p><p><element-citation id="dataset1" publication-type="data" specific-use="references"><person-group person-group-type="author"><collab>UK Biobank</collab><collab>NAOMI E. ALLEN</collab><collab>CATHIE SUDLOW</collab><collab>TIM PEAKMANRORY COLLINS et al</collab></person-group><year iso-8601-date="2014">2014</year><source>UK Biobank Data: Come and Get It</source><ext-link ext-link-type="uri" xlink:href="https://www.science.org/doi/full/10.1126/scitranslmed.3008601">https://www.science.org/doi/full/10.1126/scitranslmed.3008601</ext-link><comment>UK Biobank</comment></element-citation><element-citation id="dataset2" publication-type="data" specific-use="references"><person-group person-group-type="author"><collab>THL</collab><collab>E Vartiainen</collab><collab>P Jousilahti</collab><collab>G Alfthan</collab><collab>J Sundvall et al</collab></person-group><year iso-8601-date="2000">2000</year><source>Cardiovascular risk factor changes in Finland, 1972-1997</source><ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/10750603/">https://pubmed.ncbi.nlm.nih.gov/10750603/</ext-link><comment>FINRISK</comment></element-citation><element-citation id="dataset3" publication-type="data" specific-use="references"><person-group person-group-type="author"><collab>INTERVAL Trial Group</collab><collab>Emanuele Di Angelantonio</collab><collab>Simon G Thompson</collab><collab>Stephen Kaptoge</collab><collab>Carmel Moore et al</collab></person-group><year iso-8601-date="2017">2017</year><source>Efficiency and safety of varying the frequency of whole blood donation (INTERVAL): a randomised trial of 45000 donors</source><ext-link ext-link-type="uri" xlink:href="https://www.intervalstudy.org.uk/files/2019/11/INTERVAL-Main-Results.pdf">https://www.intervalstudy.org.uk/files/2019/11/INTERVAL-Main-Results.pdf</ext-link><comment>INTERVAL</comment></element-citation></p></sec><supplementary-material><ext-link xlink:href="elife-76272-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>